A recent pilot (n=22) double-blind study (JR Allegrett et al. Clin Gastroenterol Hepatol 2020; 18: 855-63) pours cold water on the idea that repopulating one’s microbiome would be helpful in treating obesity.
In this study, the authors examined obese patients without diabetes, nonalcoholic steatohepatitis, or metabolic syndrome. In the treatment group, patients received FMT by capsules: 30 capsules at week 4 and then a maintenance dose of 12 capsules at week 8. All FMT was derived from a single lean donor.
- There were no significant changes in mean BMI at week 12 in either group.
- Patients in the FMT group had sustained shifts in microbiomes associated with obesity toward those of the donor (P<.001). In addition, bile acid profiles became more similar to the donor.
My take: Though this was a small study, it suggests that changing the microbiome by itself is likely insufficient to result in significant weight loss.
Related blog posts:
- FMT Warning & ‘Get Your Butt in Gear’
- Could Obesity Be Cured/Created at Birth with Manipulation of Microbiome
- NY Times: Frequent Antibiotics May Make Children Fatter | gutsandgrowth
- Antibiotics Given Early in Life Linked to Childhood Obesity…Again | gutsandgrowth
- Could antibiotics make you fat? | gutsandgrowth
- Do antibiotics contribute to obesity? Not in recent study | gutsandgrowth
- Microbiome and the risk of Kwashiokor | gutsandgrowth
- Basic Science Year in Review –#NASPGHAN 2014 …
JH Beigel et al. NEJM DOI: 10.1056/NEJMoa2007764 (May 22, 2020): Full text: Remdesivir for the Treatment of Covid-19 — Preliminary Report
This was a a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement (n=1063).
- Faster recovery for remdesivir recipients: 11 days vs 15 days
- Lower mortality rate: 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70, 95% CI, 0.47 to 1.04) (mortality difference did not reach statistical significance)